Skip to Content

Posts tagged with "Diabetes and Obesity"

  • Diabetes and Obesity

    Eat It, Breath It, Soak in It?

    After Pfizer’s Exubera inhaled-insulin product died so horribly in the market last year, the other companies working in the same space had to be worried. Lilly and Alkermes have had a long-running program, as has a smaller company called Mannkind. But recently, another contender, Novo Nordisk, has announced that they and partner Aradigm have deci… Read More
  • Biological News

    Avandia: Going Under for the Third Time?

    How many hits can a drug – or a whole class of drugs – take? Avandia (rosiglitazone) has been the subject of much wrangling about cardiovascular risk in its patient population of Type II diabetics. But there have also been scattered reports of increases in fractures among people taking it or Actos (pioglitazone), the other… Read More
  • "Me Too" Drugs

    Bad Luck For Novartis – And For Diabetics

    Novartis must wonder what they did to deserve this one. A few years ago, it looked as if they ruled the potentially lucrative world of dipeptidylylpeptidase-IV (DPP-IV) inhibitors for diabetes. (Note – name of enzyme corrected after brain hiccup – DBL). Novartis seemed to be the first big company to come up with good chemical… Read More
  • Diabetes and Obesity

    Depressing Figures for Acomplia

    Back in 2005, I worried about taking a new drug to market that had a completely new central nervous system mechanism: Acomplia (rimonabant). CNS makes me nervous. I used to work in the area, and I have a healthy respect for how little we know about it. So when you come in with something new… Read More
  • Business and Markets

    Surveying the Exubera Crater

    Pfizer has pulled the inhaled insulin Exubera from the market, and not because of the FDA, and not because of the lawyers. They’re giving up on it because they can’t take the pain any more. The company sold 12 million dollars worth of the stuff so far this year, a horrifyingly tiny amount. That represents… Read More
  • Biological News

    More Things Than Are Dreamt Of

    It’s useful to be reminded every so often of how much you don’t know. There’s a new paper in PNAS that’ll do that for a number of its readers. The authors report a new protein, one of the iron-sulfur binding ones. There are quite a few of these known already, so this wouldn’t be big… Read More
  • Business and Markets

    Buying What You Can’t Make? Or What?

    I didn’t note it at the time, but Amgen just recently finished buying a smaller company, Alantos. That cost them about $300 million, and for that money they got a diabetes drug in the clinic and a program generating compounds for arthritis and other diseases. Sound OK, eh? That’s the one-line executive summary right there… Read More
  • Business and Markets

    Exubera Spirals Toward the Drainpipe

    You know, you can run the biggest marketing behemoth the drug industry has ever seen – but if people really aren’t interested in buying your product (and if insurance companies really aren’t interested in paying for it), that’s not enough. The evidence? Pfizer’s Exubera, the inhaled insulin that for years was thought b… Read More
  • Clinical Trials

    Deactivation, After All

    Four years ago I wrote about an unusual Roche diabetes compound targeting glucokinase. The odd thing about it was that it made the enzyme more active, which is something you can only rarely hope to do. Enzymes generally run near the top of their specs, unless there’s some built-in switch that keeps them damped down… Read More
  • Biological News

    Visfatin: Real Or Not?

    A commentor to my Proteomics 101 post the other day brought up an important point: that before you can have a chance to figure out what a protein is doing, you have to know that it exists. Finding the darn things is no small job, since you’re digging through piles of chemically similar stuff to… Read More